Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/Secukinumab> ?p ?o }
Showing triples 1 to 84 of
84
with 100 triples per page.
- Secukinumab abstract "Secukinumab, trade name Cosentyx, is a human IL-17 inhibiting monoclonal antibody manufactured by Novartis Pharma AG for the treatment of psoriasis. The drug is also being investigated as a treatment for uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. It targets member A form of the cytokine family of interleukin 17. It is highly specific to the human immunoglobulin G1k (IgG1k) subclass. On January 21, 2015, the United States Food and Drug Administration announced that it had approved secukinumab to treat adults with moderate-to-severe plaque psoriasis.In July 2014 secukinumab established superiority to placebo and to etanercept for the treatment of chronic plaque psoriasis in Phase III clinical trials. In October 2014, the FDA Dermatologic and Ophthalmic Drugs Advisory Committee unanimously voted to recommend the drug for FDA approval, although this vote in and of itself does not constitute an approval. However, the FDA typically follows recommendations from these committees. In October 2014, Novartis announced that the drug had achieved a primary clinical endpoint in two phase III clinical trials for ankylosing spondylitis. As of 28 October, the relevant FDA committee had not yet responded to these results. In early November 2014, Novartis also released the results of a Phase 3 study on psoriatic arthritis that yielded promising results.Although the drug was originally intended to treat rheumatoid arthritis, phase II clinical trials for this condition yielded disappointing results. Similarly, while patients in a phase II clinical trial for psoriatic arthritis did show improvement over placebo, the improvement did not meet adequate endpoints and Novartis is considering whether to do more research for this condition. Novartis has said that it is targeting approval and release in early 2015 for plaque psoriasis and ankylosing spondylitis indications. In January 2015 Novartis announced approval from the FDA to market secukinumab for moderate to severe plaque psoriasis. Secukinumab is an antibody that binds to a protein (interleukin (IL)-17A). A phase II clinical trial for multiple sclerosis completed in 2014 as it had exhibited efficacy in treating experimental autoimmune encephalomyelitis (EAE), an animal model of MS. Results of this trial have not yet been reported as of April 2015".
- Secukinumab atcPrefix "L04".
- Secukinumab atcSuffix "AC10".
- Secukinumab casNumber "875356-43-7".
- Secukinumab casSupplemental "(heavy chain)".
- Secukinumab casSupplemental "(light chain)".
- Secukinumab drugbank "DB09029".
- Secukinumab wikiPageID "33024133".
- Secukinumab wikiPageLength "8211".
- Secukinumab wikiPageOutDegree "19".
- Secukinumab wikiPageRevisionID "707386374".
- Secukinumab wikiPageWikiLink Ankylosing_spondylitis.
- Secukinumab wikiPageWikiLink Category:Immunosuppressants.
- Secukinumab wikiPageWikiLink Category:Novartis.
- Secukinumab wikiPageWikiLink Cytokine.
- Secukinumab wikiPageWikiLink Etanercept.
- Secukinumab wikiPageWikiLink Experimental_autoimmune_encephalomyelitis.
- Secukinumab wikiPageWikiLink IL17A.
- Secukinumab wikiPageWikiLink Interleukin_17.
- Secukinumab wikiPageWikiLink Monoclonal_antibody.
- Secukinumab wikiPageWikiLink Multiple_sclerosis.
- Secukinumab wikiPageWikiLink Novartis.
- Secukinumab wikiPageWikiLink Psoriasis.
- Secukinumab wikiPageWikiLink Psoriatic_arthritis.
- Secukinumab wikiPageWikiLink Rheumatoid_arthritis.
- Secukinumab wikiPageWikiLink Trade_name.
- Secukinumab wikiPageWikiLink Uveitis.
- Secukinumab wikiPageWikiLinkText "Cosentyx".
- Secukinumab wikiPageWikiLinkText "Secukinumab".
- Secukinumab wikiPageWikiLinkText "secukinumab".
- Secukinumab atcPrefix "L04".
- Secukinumab atcSuffix "AC10".
- Secukinumab c "6584".
- Secukinumab casNumber "875356".
- Secukinumab chemspiderid "none".
- Secukinumab drugbank "DB09029".
- Secukinumab h "10134".
- Secukinumab legalUs "Rx-only".
- Secukinumab mabType "mab".
- Secukinumab molecularWeight "147.94".
- Secukinumab n "1754".
- Secukinumab o "2042".
- Secukinumab pregnancyUs "B".
- Secukinumab s "44".
- Secukinumab source "u".
- Secukinumab synonyms "AIN457".
- Secukinumab target IL17A.
- Secukinumab tradename "Cosentyx".
- Secukinumab type "mab".
- Secukinumab verifiedfields "changed".
- Secukinumab verifiedrevid "464388281".
- Secukinumab wikiPageUsesTemplate Template:CAS.
- Secukinumab wikiPageUsesTemplate Template:Chemspidercite.
- Secukinumab wikiPageUsesTemplate Template:Drugbankcite.
- Secukinumab wikiPageUsesTemplate Template:Drugbox.
- Secukinumab wikiPageUsesTemplate Template:Drugs.com.
- Secukinumab wikiPageUsesTemplate Template:Monoclonals_for_immune_system.
- Secukinumab wikiPageUsesTemplate Template:Reflist.
- Secukinumab subject Category:Immunosuppressants.
- Secukinumab subject Category:Novartis.
- Secukinumab hypernym Il-.
- Secukinumab type ChemicalSubstance.
- Secukinumab type Company.
- Secukinumab type Drug.
- Secukinumab type Antibody.
- Secukinumab type Chemical.
- Secukinumab type Company.
- Secukinumab type Drug.
- Secukinumab type Immunosuppressant.
- Secukinumab type Redirect.
- Secukinumab type ChemicalObject.
- Secukinumab type Thing.
- Secukinumab type Q8386.
- Secukinumab comment "Secukinumab, trade name Cosentyx, is a human IL-17 inhibiting monoclonal antibody manufactured by Novartis Pharma AG for the treatment of psoriasis. The drug is also being investigated as a treatment for uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. It targets member A form of the cytokine family of interleukin 17. It is highly specific to the human immunoglobulin G1k (IgG1k) subclass.".
- Secukinumab label "Secukinumab".
- Secukinumab sameAs Q7444755.
- Secukinumab sameAs سکییوکروماب.
- Secukinumab sameAs Secukinumab.
- Secukinumab sameAs セクキヌマブ.
- Secukinumab sameAs Secuquinumab.
- Secukinumab sameAs m.0h560sz.
- Secukinumab sameAs Q7444755.
- Secukinumab wasDerivedFrom Secukinumab?oldid=707386374.
- Secukinumab isPrimaryTopicOf Secukinumab.